7BFY image
Deposition Date 2021-01-05
Release Date 2021-04-07
Last Version Date 2024-01-31
Entry Detail
PDB ID:
7BFY
Title:
Structure of the apo form of the N terminal domain of Bc2L-C lectin (1-131)
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.50 Å
R-Value Free:
0.17
R-Value Work:
0.14
R-Value Observed:
0.15
Space Group:
P 63
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Lectin
Gene (Uniprot):BCAM0185
Chain IDs:A
Chain Length:131
Number of Molecules:1
Biological Source:Burkholderia cenocepacia J2315
Primary Citation
Prediction and Validation of a Druggable Site on Virulence Factor of Drug Resistant Burkholderia cenocepacia*.
Chemistry 27 10341 10348 (2021)
PMID: 33769626 DOI: 10.1002/chem.202100252

Abstact

Burkholderia cenocepacia is an opportunistic Gram-negative bacterium that causes infections in patients suffering from chronic granulomatous diseases and cystic fibrosis. It displays significant morbidity and mortality due to extreme resistance to almost all clinically useful antibiotics. The bacterial lectin BC2L-C expressed in B. cenocepacia is an interesting drug target involved in bacterial adhesion and subsequent deadly infection to the host. We solved the first high resolution crystal structure of the apo form of the lectin N-terminal domain (BC2L-C-nt) and compared it with the ones complexed with carbohydrate ligands. Virtual screening of a small fragment library identified potential hits predicted to bind in the vicinity of the fucose binding site. A series of biophysical techniques and X-ray crystallographic screening were employed to validate the interaction of the hits with the protein domain. The X-ray structure of BC2L-C-nt complexed with one of the identified active fragments confirmed the ability of the site computationally identified to host drug-like fragments. The fragment affinity could be determined by titration microcalorimetry. These structure-based strategies further provide an opportunity to elaborate the fragments into high affinity anti-adhesive glycomimetics, as therapeutic agents against B. cenocepacia.

Legend

Protein

Chemical

Disease

Primary Citation of related structures